Here comes the oral GLP-1 drug for diabetes — and Novo Nordisk wants to price Rybelsus 'at a similar level as Ozempic'
Novo Nordisk’s priority review voucher on oral semaglutide has paid off. The FDA approval for the GLP-1 drug hit late Friday morning, around six months after the NDA filing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,400+ biopharma pros reading Endpoints daily — and it's free.